DK1412493T3 - Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer - Google Patents
Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemerInfo
- Publication number
- DK1412493T3 DK1412493T3 DK02763401.3T DK02763401T DK1412493T3 DK 1412493 T3 DK1412493 T3 DK 1412493T3 DK 02763401 T DK02763401 T DK 02763401T DK 1412493 T3 DK1412493 T3 DK 1412493T3
- Authority
- DK
- Denmark
- Prior art keywords
- vectors
- production systems
- promoters
- methods
- lentiviral vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30956901P | 2001-08-02 | 2001-08-02 | |
| PCT/US2002/024275 WO2003012054A2 (en) | 2001-08-02 | 2002-08-01 | Methods and compositions relating to improved lentiviral vector production systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1412493T3 true DK1412493T3 (da) | 2012-01-09 |
Family
ID=23198746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02763401.3T DK1412493T3 (da) | 2001-08-02 | 2002-08-01 | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7629153B2 (da) |
| EP (1) | EP1412493B1 (da) |
| AT (1) | ATE527347T1 (da) |
| AU (1) | AU2002327412A1 (da) |
| CA (1) | CA2456169C (da) |
| DK (1) | DK1412493T3 (da) |
| IL (2) | IL160132A0 (da) |
| WO (1) | WO2003012054A2 (da) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| AU2002327412A1 (en) | 2001-08-02 | 2003-02-17 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
| CA2915676C (en) | 2001-10-02 | 2017-06-06 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| GB0702694D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Vectors |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| ATE553771T1 (de) | 2007-06-06 | 2012-05-15 | Res Dev Foundation | Rtef-1-varianten und deren verwendung zur inhibierung von angiogenese |
| US8785385B2 (en) | 2010-04-19 | 2014-07-22 | Research Development Foundation | RTEF-1 variants and uses thereof |
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| EP2895191B1 (en) | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury protein, adenoviral vectors encoding brachyury protein, and their use |
| ES2854754T3 (es) | 2012-10-24 | 2021-09-22 | Platelet Targeted Therapeutics Llc | Tratamiento dirigido a plaquetas |
| GB201318804D0 (en) * | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
| EP3800191A1 (en) | 2014-03-17 | 2021-04-07 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| AU2015311706A1 (en) | 2014-09-07 | 2017-02-02 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
| CN108289940B (zh) | 2015-08-03 | 2023-01-13 | 美国卫生和人力服务部 | Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途 |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| EP3211000B1 (en) | 2016-02-25 | 2019-01-30 | Provecs Medical GmbH | Novel immunostimulating vector system |
| EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| JP7045362B2 (ja) | 2016-04-20 | 2022-03-31 | セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． | Ｐｋｌｒの遺伝子発現増強のための組成物および方法 |
| ES2908467T3 (es) | 2016-04-29 | 2022-04-29 | Adverum Biotechnologies Inc | Evasión de anticuerpos neutralizantes por un virus adenoasociado recombinante |
| AU2017345470B2 (en) | 2016-10-19 | 2023-08-03 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| KR20240015743A (ko) | 2017-01-07 | 2024-02-05 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
| US10675328B2 (en) | 2017-02-14 | 2020-06-09 | Children's Hospital Medical Center | Compositions and methods for treatment of Gcase related disease states |
| MX2019011040A (es) | 2017-03-17 | 2020-01-20 | Adverum Biotechnologies Inc | Composiciones y metodos para potenciar la expresion genica. |
| CA3057171A1 (en) | 2017-03-30 | 2018-10-04 | The University Of Queensland | Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof |
| GB201706394D0 (en) | 2017-04-21 | 2017-06-07 | Ospedale San Raffaele Srl | Gene Therapy |
| EP3687561A4 (en) | 2017-09-01 | 2021-06-09 | The Australian National University | "immunoregulatory molecules and uses therefor" |
| CA3068498A1 (en) * | 2017-10-03 | 2019-04-11 | Abbott Molecular Inc. | Assay for detecting human immunodeficiency virus (hiv) |
| US20190142974A1 (en) | 2017-10-13 | 2019-05-16 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| EP3697452A4 (en) | 2017-10-16 | 2021-11-24 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. | LENTIVIRAL VECTORS FOR THE ADMINISTRATION OF PKLR TO TREAT PYRUVATE KINASE DEFICIENCY |
| EP3728595A1 (en) | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
| CA3084632A1 (en) | 2017-12-21 | 2019-06-27 | Crispr Therapeutics Ag | Materials and methods for treatment of usher syndrome type 2a |
| EP3758682A4 (en) | 2018-02-26 | 2021-12-15 | Antolrx, Inc. | TOLEROGENIC LIPOSOMES AND THEIR PROCEDURES FOR USE |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020059848A1 (ja) * | 2018-09-20 | 2020-03-26 | 国立大学法人東京医科歯科大学 | レンチウイルスベクター産生の増強方法 |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| US20230026259A1 (en) | 2019-03-08 | 2023-01-26 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CN114174327A (zh) | 2019-03-08 | 2022-03-11 | 黑曜石疗法公司 | 用于可调整调控的cd40l组合物和方法 |
| CN114126666A (zh) | 2019-04-28 | 2022-03-01 | 西莱克塔生物科技公司 | 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法 |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| EP3976802A1 (en) | 2019-05-28 | 2022-04-06 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| US20220259284A1 (en) | 2019-06-12 | 2022-08-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20220267398A1 (en) | 2019-06-12 | 2022-08-25 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| JP2022547154A (ja) | 2019-09-10 | 2022-11-10 | オブシディアン セラピューティクス， インコーポレイテッド | 調節可能な制御のためのｃａ２－ｉｌ１５融合タンパク質 |
| AU2020361533A1 (en) | 2019-10-08 | 2022-04-28 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| AU2021205416A1 (en) | 2020-01-08 | 2022-08-25 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
| CA3185267A1 (en) | 2020-08-07 | 2022-02-10 | Spacecraft Seven, Llc | Plakophilin-2 (pkp2) gene therapy using aav vector |
| WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
| AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
| CA3217862A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
| CA3225985A1 (en) | 2021-07-01 | 2023-01-05 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| EP4384193A2 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| US20240425820A1 (en) | 2021-08-11 | 2024-12-26 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| JP2024531234A (ja) | 2021-08-11 | 2024-08-29 | サナ バイオテクノロジー，インコーポレイテッド | 同種異系細胞療法のための遺伝子改変された初代細胞 |
| US20240358761A1 (en) | 2021-08-11 | 2024-10-31 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| US20250009802A1 (en) | 2021-12-16 | 2025-01-09 | Ludwig Institute For Cancer Research Ltd | Antisense transfer vectors and methods of use thereof |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| AU2023220128A1 (en) | 2022-02-17 | 2024-08-22 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
| GB202206346D0 (en) | 2022-04-29 | 2022-06-15 | Ospedale San Raffaele Srl | Gene therapy |
| AU2023299307A1 (en) | 2022-06-30 | 2025-01-09 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024151541A1 (en) | 2023-01-09 | 2024-07-18 | Sana Biotechnology, Inc. | Type-1 diabetes autoimmune mouse |
| WO2024229302A1 (en) | 2023-05-03 | 2024-11-07 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| WO2024243236A2 (en) | 2023-05-22 | 2024-11-28 | Sana Biotechnology, Inc. | Methods of delivery of islet cells and related methods |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4682195A (en) | 1985-09-30 | 1987-07-21 | General Electric Company | Insulated gate device with configured emitter contact pad |
| US5019384A (en) | 1986-06-30 | 1991-05-28 | Massachusetts Institute Of Technology | Immunonodulating compositions and their use |
| EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
| NL8603180A (nl) * | 1986-12-15 | 1988-07-01 | Philips Nv | Meerkleurenafbeeldinrichting, voorzien van een beheerinrichting voor kleurselektie. |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| CA2051288C (en) | 1990-09-14 | 2002-02-05 | Robert L. Martuza | Viral targeted destruction of neoplastic cells |
| US5885570A (en) | 1991-01-23 | 1999-03-23 | The General Hospital Corporation | Induction of tolerance with modified immunogens |
| DE4204650C1 (da) | 1992-02-15 | 1993-07-08 | Hoffmeister, Helmut, Dr., 4400 Muenster, De | |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5912411A (en) | 1993-06-14 | 1999-06-15 | University Of Heidelberg | Mice transgenic for a tetracycline-inducible transcriptional activator |
| US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| GB9510272D0 (en) | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5705629A (en) | 1995-10-20 | 1998-01-06 | Hybridon, Inc. | Methods for H-phosphonate synthesis of mono- and oligonucleotides |
| GB9525639D0 (en) | 1995-12-15 | 1996-02-14 | Isis Innovation | Improved retroviral vectors |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| ES2153654T3 (es) | 1996-10-17 | 2001-03-01 | Oxford Biomedica Ltd | Vectores retrovirales. |
| US5846225A (en) | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
| US6017758A (en) | 1997-02-20 | 2000-01-25 | Vanderbilt University | DMNPE caged nucleic acid and vector |
| US20020123471A1 (en) | 1997-03-06 | 2002-09-05 | Klaus Uberla | Lentivirus based vector and vector system |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| US6531123B1 (en) | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
| KR100556864B1 (ko) | 1997-05-13 | 2006-03-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 렌티바이러스-기원 유전자 전달 벡터 |
| US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
| CA2292760A1 (en) | 1997-06-04 | 1998-12-10 | Oxford Biomedica (Uk) Limited | Vector |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| JP2001510053A (ja) | 1997-07-18 | 2001-07-31 | カイロン コーポレイション | レンチウイルスベクター |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CA2315269A1 (en) | 1997-12-22 | 1999-07-01 | Oxford Biomedica (Uk) Limited | Equine infectious anaemia virus (eiav) based |
| US20020048805A1 (en) * | 1998-01-16 | 2002-04-25 | Julie C. Johnston | Feline immunodeficiency virus gene therapy vectors |
| EP1045921A2 (en) | 1998-01-16 | 2000-10-25 | Chiron Corporation | Feline immunodeficiency virus gene therapy vectors |
| US6084063A (en) | 1998-02-06 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitors of allergic reactions |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| WO1999051754A1 (en) | 1998-04-02 | 1999-10-14 | Dana-Farber Cancer Institute, Inc. | Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US6555342B1 (en) | 1998-06-03 | 2003-04-29 | Uab Research Foundation | Fusion protein delivery system and uses thereof |
| US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| CA2340596A1 (en) | 1998-08-26 | 2000-03-09 | Bavarian Nordic Research Institute A/S | Guanylate binding protein (gbp-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
| AU6139699A (en) | 1998-09-11 | 2000-04-03 | Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
| EP2386646B1 (en) | 1998-10-01 | 2016-12-21 | University Of Southern California | Gene delivery system and methods of use |
| GB9825524D0 (en) | 1998-11-20 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
| DE19856463B4 (de) | 1998-11-26 | 2006-02-02 | Heinrich-Pette-Institut | Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren |
| WO2000055335A1 (en) | 1999-03-16 | 2000-09-21 | Dana-Farber Cancer Institute, Inc. | Pseudotyped lentiviral vectors and uses thereof |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| AU4559800A (en) | 1999-04-29 | 2000-11-17 | Aarhus Universitet | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
| EP1059357A1 (en) * | 1999-06-09 | 2000-12-13 | Universite Pierre Et Marie Curie Paris Vi | Replicating or semi-replicating retroviral constructs, preparation and uses for gene delivery |
| PT1092779E (pt) | 1999-10-11 | 2010-01-19 | Pasteur Institut | Vectores lentivíricos para a preparação de composições imunoterapêuticas |
| DK1224314T3 (da) | 1999-10-12 | 2007-05-21 | Inst Nat Sante Rech Med | Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA |
| WO2001034843A1 (en) | 1999-11-10 | 2001-05-17 | The Uab Research Foundation | Lentiviral vector transduction of hematopoietic stem cells |
| US6218186B1 (en) | 1999-11-12 | 2001-04-17 | Trustees Of The University Of Pennsylvania | HIV-MSCV hybrid viral vector for gene transfer |
| US6864085B2 (en) | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
| ES2340073T3 (es) | 1999-12-14 | 2010-05-28 | Novartis Ag | Vectores basados en virus de inmunodeficiencia bovina (vib). |
| CA2398790A1 (en) | 2000-01-28 | 2001-08-02 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| WO2001085974A2 (en) | 2000-05-12 | 2001-11-15 | University Of Southern California | Retroviral vectors comprising an enhanced 3' transcription termination structure |
| AU2001265190A1 (en) | 2000-05-30 | 2001-12-11 | University Of Rochester | Siv derived lentiviral vector systems |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| EP1354038A2 (en) | 2000-12-28 | 2003-10-22 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
| US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| JP3765574B2 (ja) | 2001-02-22 | 2006-04-12 | 三菱化学株式会社 | 逆向き反復配列を含む組み換え遺伝子及びその利用 |
| US20030039636A1 (en) | 2001-05-01 | 2003-02-27 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (SIN) lentiviral vectors |
| US20030119770A1 (en) | 2001-08-02 | 2003-06-26 | Zhennan Lai | Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors |
| AU2002327412A1 (en) | 2001-08-02 | 2003-02-17 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
| US7732193B2 (en) | 2001-09-13 | 2010-06-08 | California Institute Of Technology | Method for expression of small RNA molecules within a cell |
| WO2003072788A1 (en) | 2002-02-21 | 2003-09-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for reversibly controlling expression of target genes in cells |
-
2002
- 2002-08-01 AU AU2002327412A patent/AU2002327412A1/en not_active Abandoned
- 2002-08-01 DK DK02763401.3T patent/DK1412493T3/da active
- 2002-08-01 CA CA2456169A patent/CA2456169C/en not_active Expired - Lifetime
- 2002-08-01 AT AT02763401T patent/ATE527347T1/de not_active IP Right Cessation
- 2002-08-01 WO PCT/US2002/024275 patent/WO2003012054A2/en not_active Application Discontinuation
- 2002-08-01 EP EP02763401A patent/EP1412493B1/en not_active Expired - Lifetime
- 2002-08-01 IL IL16013202A patent/IL160132A0/xx unknown
- 2002-08-01 US US10/209,952 patent/US7629153B2/en not_active Expired - Lifetime
-
2004
- 2004-01-29 IL IL160132A patent/IL160132A/en active IP Right Grant
-
2009
- 2009-10-13 US US12/578,346 patent/US8900858B2/en not_active Expired - Lifetime
-
2014
- 2014-10-28 US US14/525,520 patent/US9260725B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IL160132A0 (en) | 2004-06-20 |
| US20030082789A1 (en) | 2003-05-01 |
| IL160132A (en) | 2012-01-31 |
| EP1412493B1 (en) | 2011-10-05 |
| CA2456169C (en) | 2012-05-22 |
| AU2002327412A1 (en) | 2003-02-17 |
| US20150203870A1 (en) | 2015-07-23 |
| US9260725B2 (en) | 2016-02-16 |
| ATE527347T1 (de) | 2011-10-15 |
| EP1412493A2 (en) | 2004-04-28 |
| US8900858B2 (en) | 2014-12-02 |
| US20100062524A1 (en) | 2010-03-11 |
| EP1412493A4 (en) | 2005-11-23 |
| WO2003012054A2 (en) | 2003-02-13 |
| CA2456169A1 (en) | 2003-02-13 |
| US7629153B2 (en) | 2009-12-08 |
| WO2003012054A3 (en) | 2003-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1412493T3 (da) | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer | |
| Moroz-Omori et al. | Photoswitchable gRNAs for spatiotemporally controlled CRISPR-Cas-based genomic regulation | |
| Moelling et al. | RNase H as gene modifier, driver of evolution and antiviral defense | |
| Xie et al. | Novel epigenetic techniques provided by the CRISPR/Cas9 system | |
| Park et al. | Staufen‐mediated mRNA decay | |
| Ladomery | Aberrant alternative splicing is another hallmark of cancer | |
| WO2003029412A3 (en) | Restricted expression lentivial vectors | |
| Kushwaha et al. | The replication initiator protein of a geminivirus interacts with host monoubiquitination machinery and stimulates transcription of the viral genome | |
| ES2906263T3 (es) | Silenciamiento génico epigénico permanente | |
| ATE484596T1 (de) | Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom | |
| BR112021006844A2 (pt) | métodos para editar um rna alvo e para tratar ou prevenir uma doença ou condição, rna editado ou uma célula hospedeira tendo um rna editado, rna que recruta desaminase, construção, biblioteca, composição, célula hospedeira, e, kit para editar um rna alvo . | |
| CL2020002704A1 (es) | Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial | |
| JP2019531068A5 (da) | ||
| Kranzusch et al. | Assembly of a functional Machupo virus polymerase complex | |
| BR112018010635A2 (pt) | linhagens celulares estáveis para a produção retroviral | |
| BRPI0514396A2 (pt) | polipeptìdeos dependentes de vitamina k modificada | |
| NO20074654L (no) | Lenteviral-vektorer og deres anvendelse | |
| Berry et al. | Viral suppressors of RNA silencing hinder exogenous and endogenous small RNA pathways in Drosophila | |
| Geerts-Dimitriadou et al. | Analysis of the Tomato spotted wilt virus ambisense S RNA-encoded hairpin structure in translation | |
| CO6270367A2 (es) | Genes de dc-sign icam-3 y lsectin porcinas y usos de los mismos | |
| JP2018534937A5 (da) | ||
| Peze-Heidsieck et al. | Retrotransposons as a Source of DNA Damage in Neurodegeneration | |
| Aurélie et al. | Lentiviral vectors: a powerful tool to target astrocytes in vivo | |
| Xiang et al. | The regulation and functions of endogenous retrovirus in embryo development and stem cell differentiation | |
| English et al. | A (dis) integrated stress response: genetic diseases of eIF2α regulators |